International Journal of Clinical Pharmacy

, Volume 37, Issue 5, pp 758–761 | Cite as

Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?

  • Ho Choi
  • JiHyeon Ryu
  • Heenam Seo
  • MinKu Kang
  • Eunyoung KimEmail author
Short Research Report


Background A double maintenance dose of clopidogrel at 150 mg daily has been suggested as an effective alternative treatment for patients who have clopidogrel resistance. Objective To determine if a double maintenance dose of clopidogrel can overcome the low drug response rate observed in patients who have clopidogrel resistance while on a 75 mg daily standard maintenance dose of clopidogrel. Methods A retrospective analysis was conducted in South Korean patients who underwent a platelet function test and received a double maintenance dose of clopidogrel at a secondary medical institution between January 2011 and June 2012. The primary endpoint was to assess clopidogrel response using an adenosine diphosphate test after a double maintenance dose of clopidogrel. The secondary endpoint was the presence of factors that could affect response to clopidogrel. Results Of 389 patients identified, 77 patients were eligible for this study. Values from the adenosine diphosphate test decreased significantly in 63 patients (82 %) after a double maintenance dose of clopidogrel (p < 0.001). A total of 37 patients (48 %) overcame clopidogrel resistance. Concurrent disease appeared to be a contributory factor in clopidogrel resistance. Conclusion A double maintenance dose of clopidogrel at 150 mg daily was associated with a reduction in adenosine diphosphate-induced platelet aggregation in South Korean patients who previously exhibited clopidogrel resistance.


Clopidogrel resistance High maintenance dose South Korea 



The authors would like to thank director Kyung-lae Jung in division of pharmacy and medical teams from the Sun Medical Center, Daejeon for providing feedback on the manuscript.


The author(s) received no financial support for the research, authorship, and/or publication of this article.

Conflicts of interest

The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


  1. 1.
    Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003;3:113–22.CrossRefPubMedGoogle Scholar
  2. 2.
    O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–425.CrossRefPubMedGoogle Scholar
  3. 3.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–16.CrossRefPubMedGoogle Scholar
  4. 4.
    De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost. 2008;100:196–203.PubMedGoogle Scholar
  5. 5.
    Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb Haemost. 2010;103:841–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Tavassoli N, Voisin S, Carrie D, Lapeyre MM, Galinier M, Montastruc JL. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. Am J Cardiovasc Drugs. 2010;10:29–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097–105.CrossRefPubMedGoogle Scholar
  8. 8.
    Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822–34.CrossRefPubMedGoogle Scholar
  9. 9.
    Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376:1233–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Wilffert B, Swen J, Mulder H, Touw D, Maitland-Vander Zee AH, Deneer V. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int J Clin Pharm. 2011;33(1):3–9.CrossRefPubMedGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2015

Authors and Affiliations

  • Ho Choi
    • 1
  • JiHyeon Ryu
    • 2
  • Heenam Seo
    • 2
  • MinKu Kang
    • 3
  • Eunyoung Kim
    • 2
    Email author
  1. 1.Department of PharmacySun HospitalDaejeonSouth Korea
  2. 2.Clinical Pharmacy and Evidence Based Practice Research Lab, College of PharmacyChungAng UniversitySeoulSouth Korea
  3. 3.College of PharmacyWoosuk UniversityWonju-gunSouth Korea

Personalised recommendations